XBIT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XBIT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, XBiotech's Trailing 12-Month Free Cash Flow is $-29.19 Mil, and Market Cap is $211.86 Mil. Therefore, XBiotech's FCF Yield % for today is -13.78%.
The historical rank and industry rank for XBiotech's FCF Yield % or its related term are showing as below:
During the past 12 years, the highest FCF Yield % of XBiotech was 37.14%. The lowest was -19.57%. And the median was -10.89%.
XBiotech's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for XBiotech's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBiotech Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -2.38 | -15.02 | 19.46 | -14.42 | -15.68 |
XBiotech Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Yield % | Get a 7-Day Free Trial | -4.85 | -11.66 | -12.05 | -30.66 | -10.50 |
For the Biotechnology subindustry, XBiotech's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, XBiotech's FCF Yield % distribution charts can be found below:
* The bar in red indicates where XBiotech's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
XBiotech's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -19.087 | / | 121.748 | |
= | -15.68% |
XBiotech's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -6.183 | * | 4 | / | 235.605762 | |
= | -10.50% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBiotech FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of XBiotech's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Angela Hu | officer: Principle Financial Officer | 5217 WINNEBAGO LN, AUSTIN TX 78744 |
John Simard | director, 10 percent owner | 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744 |
Bay Street Financial S.a. | 10 percent owner | MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ |
W Thorpe Mckenzie | director, 10 percent owner | 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402 |
Sushma Shivaswamy | officer: VP of R&D | 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744 |
Queena Han | officer: VP of Fin & HR, Secretary | 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744 |
Thomas Gut | 10 percent owner | CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001 |
Peter Libby | director | 109 LARCH ROAD, CAMBRIDGE MA 02138 |
Fondation Rennes | 10 percent owner | RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490 |
Donald H. Macadam | director | 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5 |
Jan-paul Waldin | director | 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8 |
Benjamin Guzman | officer: Sr.VP Corp. Strategy & Finance | 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744 |
Trey Benson | officer: VP of Commercial Development | 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744 |
Kalidip Choudhury | officer: VP of Business Development | 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744 |
Dawn Mccollough | officer: VP Clinical Operations | 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703 |
From GuruFocus
By Marketwired Marketwired • 09-08-2021
By GlobeNewswire • 08-08-2023
By GlobeNewswire GlobeNewswire • 06-30-2021
By sperokesalga sperokesalga • 05-22-2023
By Marketwired • 06-18-2024
By GuruFocusNews GuruFocusNews • 02-02-2022
By sperokesalga sperokesalga • 04-17-2023
By Marketwired Marketwired • 08-30-2021
By Marketwired Marketwired • 06-23-2021
By Marketwired Marketwired • 10-28-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.